InvestorsHub Logo
Followers 26
Posts 645
Boards Moderated 0
Alias Born 11/22/2014

Re: BlackMountain post# 432365

Thursday, 01/06/2022 2:17:35 AM

Thursday, January 06, 2022 2:17:35 AM

Post# of 731092
What I take from the press release is Nejm is backing a more progesssive way to evaluate clinical trials. And more spescific to cell and gene therapy trials.
They are promoting a new cutting edge peer revued paper that proposes why new clinical trial endpoints should be accepted before trials are unblinded.
A precussor journal article before the big show.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News